Literature DB >> 11692239

Rapid MRI using a modified Dixon technique: a non-invasive and effective method for detection and monitoring of fatty metamorphosis of the liver.

M H Fishbein1, W R Stevens.   

Abstract

Fatty liver and non-alcoholic steatohepatitis are frequently associated with obesity. Weight loss is the mainstay of therapy for these conditions. In this case report, we used a modification of the Dixon method to demonstrate normalization of hepatic fat content in an obese individual with fatty liver following weight reduction. This technique involves fast gradient echo instead of spin echo, which has been utilized previously, as the former provides an accurate and more rapid means of assessing hepatic fat content. This technique is recommended for the assessment of hepatic steatosis in at-risk subjects.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11692239     DOI: 10.1007/s002470100547

Source DB:  PubMed          Journal:  Pediatr Radiol        ISSN: 0301-0449


  19 in total

Review 1.  Liver fat content determined by magnetic resonance imaging and spectroscopy.

Authors:  Fabian Springer; Jürgen Machann; Claus D Claussen; Fritz Schick; Nina F Schwenzer
Journal:  World J Gastroenterol       Date:  2010-04-07       Impact factor: 5.742

Review 2.  Drug interventions for the treatment of obesity in children and adolescents.

Authors:  Emma Mead; Greg Atkinson; Bernd Richter; Maria-Inti Metzendorf; Louise Baur; Nicholas Finer; Eva Corpeleijn; Claire O'Malley; Louisa J Ells
Journal:  Cochrane Database Syst Rev       Date:  2016-11-29

3.  Choline Supplementation With a Structured Lipid in Children With Cystic Fibrosis: A Randomized Placebo-Controlled Trial.

Authors:  Joan I Schall; Maria R Mascarenhas; Asim Maqbool; Kelly A Dougherty; Okan Elci; Dah-Jyuu Wang; Talissa A Altes; Kevin A Hommel; Walter Shaw; Jeff Moore; Virginia A Stallings
Journal:  J Pediatr Gastroenterol Nutr       Date:  2016-04       Impact factor: 2.839

4.  Evaluation of portal venous velocity with Doppler ultrasound in patients with nonalcoholic fatty liver disease.

Authors:  Serife Ulusan; Tolga Yakar; Zafer Koc
Journal:  Korean J Radiol       Date:  2011-07-22       Impact factor: 3.500

5.  Pediatric nonalcoholic fatty liver disease: A clinical and laboratory challenge.

Authors:  Lucia Pacifico; Eleonora Poggiogalle; Vito Cantisani; Guendalina Menichini; Paolo Ricci; Flavia Ferraro; Claudio Chiesa
Journal:  World J Hepatol       Date:  2010-07-27

6.  T1-weighted dual-echo MRI for fat quantification in pediatric nonalcoholic fatty liver disease.

Authors:  Lucia Pacifico; Michele Di Martino; Carlo Catalano; Valeria Panebianco; Mario Bezzi; Caterina Anania; Claudio Chiesa
Journal:  World J Gastroenterol       Date:  2011-07-07       Impact factor: 5.742

7.  Estimation of hepatic proton-density fat fraction by using MR imaging at 3.0 T.

Authors:  Takeshi Yokoo; Masoud Shiehmorteza; Gavin Hamilton; Tanya Wolfson; Michael E Schroeder; Michael S Middleton; Mark Bydder; Anthony C Gamst; Yuko Kono; Alexander Kuo; Heather M Patton; Santiago Horgan; Joel E Lavine; Jeffrey B Schwimmer; Claude B Sirlin
Journal:  Radiology       Date:  2011-01-06       Impact factor: 11.105

Review 8.  The metabolic syndrome and nonalcoholic fatty liver disease in children.

Authors:  Shikha S Sundaram; Phil Zeitler; Kristen Nadeau
Journal:  Curr Opin Pediatr       Date:  2009-08       Impact factor: 2.856

9.  A paradoxical signal intensity increase in fatty livers using opposed-phase gradient echo imaging with fat-suppression pulses.

Authors:  Robert V Mulkern; Sandra Loeb Salsberg; Marta Ramon Krauel; David S Ludwig; Stephan Voss
Journal:  Pediatr Radiol       Date:  2008-08-02

10.  Glucose dysregulation and hepatic steatosis in obese adolescents: is there a link?

Authors:  Anna M G Cali; Ana Mayra De Oliveira; Hyeonjin Kim; Shu Chen; Miguel Reyes-Mugica; Sandra Escalera; James Dziura; Sara E Taksali; Romy Kursawe; Melissa Shaw; Mary Savoye; Bridget Pierpont; R Todd Constable; Sonia Caprio
Journal:  Hepatology       Date:  2009-06       Impact factor: 17.425

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.